Bottom line
A marketed three-component research-peptide combination (GHK-Cu, BPC-157, TB-500) sold as a single Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. 定义来源: Lyophilization, formulation, and stability primer · 术语表 vial under the name "GLOW." Composition ratios vary by vendor and batch. There is no published peer-reviewed study of this exact three-component combination. Each component has independent Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. 定义来源: Evidence grading methodology · 术语表 evidence; combination-specific synergy is theoretical.
No established or recommended human dose.
Name and formulation variability
"GLOW" is a vendor-coined marketing name. No pharmacopoeial or regulatory standard exists. Observed formulations:
| Market observation (source/date) | Claimed composition | Evidence type | Verification limits |
|---|---|---|---|
| 2026 listing — Aventris Labs | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg | Seller declaration | Unverified |
| 2026 listing — D&L Peptides | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg | Seller declaration | Unverified |
| 2026 listing — Durham Peptides | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg | Seller declaration | Unverified |
| 2026 listing — Legion Peptides | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg (70 mg total claimed) | Seller declaration | Identity and purity unverified |
| 2026 report — Skye batch GLOW25-40-004 | GHK-Cu 33.8 mg, BPC-157 6.7 mg, TB-500 10.7 mg | Seller-supplied test report | Method and custody limits apply; not independently corroborated |
| 2026 report — Skye batch GLOW25-70-005 | GHK-Cu 60.4 mg, BPC-157 11.0 mg, TB-500 10.4 mg | Seller-supplied test report | Method and custody limits apply; not independently corroborated |
Ratios vary: GHK-Cu ranges from ~33.8 to ~62 mg; BPC-157 from ~6.7 to ~11.9 mg; TB-500 from ~10.4 to ~10.7 mg across observed batches. No standard formulation exists.
GHK-Cu, BPC-157, and identity-ambiguous TB-500 each have separate evidence. Their marketed overlap is called GLOW, but no triple-combination study or independent co-formulation stability study was identified.
Component evidence
| Component | Separate evidence | Combination evidence | Compatibility |
|---|---|---|---|
| GHK-Cu | Separate evidence domains: copper-tripeptide identity, matrix biology, antioxidant gene expression, and MMP activity | Not identified for this triple combination | No independent published co-formulation stability study |
| BPC-157 | Separate Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. 定义来源: Evidence grading methodology · 术语表 domains: VEGFR2/NO pathway hypotheses, GI models, and tendon models | Not identified for this triple combination | No published interaction data with GHK-Cu or TB-500 in solution |
| TB-500 | Separate evidence domains plus a threshold identity ambiguity: full-length thymosin beta-4 versus a short fragment | Not identified for this triple combination | Exact identity and ratio interpretation remain unresolved |
Combination-specific studies
No published peer-reviewed study tests the specific GHK-Cu + BPC-157 + TB-500 triple combination against individual components or An inactive comparator used in a controlled study. 定义来源: Neutral gloss; usage context: Evidence grading methodology · 术语表. The combination rationale is mechanistic extrapolation: GHK-Cu for matrix remodelling, BPC-157 for angiogenesis, TB-500 for cell migration.
Safety and interaction uncertainties
Identity
TB-500 may refer to full-length thymosin beta-4 or a short fragment
Seller declarations and seller-supplied reports do not independently verify each component's identity
Biological interaction
No combination-specific toxicology data
Individual component safety profiles (Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. 定义来源: Evidence grading methodology · 术语表 only) do not predict combination safety
Product quality
GHK-Cu imparts a blue colour to the material that may interfere with visual inspection
Co-formulation compatibility and stability have not been independently characterised
Regulatory and product-quality notes
None of the three components is FDA-approved for any therapeutic indication
All are sold as "research use only" products outside pharmaceutical regulation
The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. 定义来源: WADA and sport regulation brief · 术语表: BPC-157 is listed under WADA Prohibited List class S0 (non-approved substances): pharmacological substances not addressed elsewhere in the list and with no current approval by any governmental regulatory health authority for human therapeutic use. 定义来源: WADA and sport regulation brief · 术语表; thymosin-β4 and derivatives such as TB-500 are listed under S2.3. GHK-Cu is not explicitly named in the 2026 List, so its status should not be inferred from this marketed blend name.
Purity claims are unverified vendor or test-provider reports and have not been independently corroborated
Evidence gaps
No controlled study of the triple combination
No How a substance is absorbed, distributed, metabolized, and eliminated by the body; atlas pages report pharmacokinetic data such as half-life, metabolism, and clearance. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 study of combined administration
No stability study of co-Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. 定义来源: Lyophilization, formulation, and stability primer · 术语表 or co-The product-specific pharmaceutical process by which a lyophilized (freeze-dried) solid returns to a liquid dispersion. It is not evidence that the resulting material is suitable for administration. 定义来源: What reconstitution means primer · 术语表 material
No human clinical data for any of the three components for tissue-repair claims
Compare the related market names Wolverine and KLOW, and see Peptide Blend Names Decoded for the broader naming problem.
Sources
Legion Peptides. GLOW70 product page. https://legionpeptides.com/multi-peptide-blends/glow/ accessed 2026-08-06.
Skye Peptides. GLOW GHK-Cu / TB-500 / BPC-157 product page. https://skyepeptidesltd.com/product/glow-ghk-cu-tb-500-bpc-157/ accessed 2026-08-06.
Durham Peptides. GLOW Blend Composition. https://www.durhampeptides.ca/post/glow-blend-composition accessed 2026-08-06.
Aventris Labs. GLOW Blend product page. https://aventrislabs.com/product/glow-blend-bpc-157-tb-500-ghk-cu-70mg/ accessed 2026-08-06.
D&L Peptides. GLOW Research Blend. https://dlpeptides.com/peptides/glow-peptide/ accessed 2026-08-06.
Miro Biotech. GLOW Blend. https://www.mirobiotech.com/products/glow accessed 2026-08-06.
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf